Abzena's New Scientific Advisory Board to Drive Growth Forward

Author: Dylan Bailey Updated: 05-15-2025 10:42 AM

Abzena Establishes a Strategic Scientific Advisory Board

Abzena, a leader in integrated CDMO and CRO services for complex biologics, is excited to share the creation of its new Scientific Advisory Board (SAB). This board comprises experienced professionals from the biopharma industry, each offering diverse expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The establishment of this advisory board signals Abzena's dedication to fostering innovation and supporting its growth strategies effectively.

Driving Innovation Through Expertise

Matt Stober, the CEO of Abzena, expressed the strategic importance of this new board. He mentioned, "The formation of the Scientific Advisory Board is aimed at steering Abzena's future. We have observed significant progress in our ability to support intricate and innovative therapy modalities, including Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecific therapies. Our goal is to keep enhancing these capabilities, providing top-notch technologies to benefit our customers’ initiatives. These experts will play a vital role in refining our strategies and suggesting actions to further expedite the pathway of medicines to patients."

Industry Leaders Join the Board

Joe Principe, Abzena's Chief Commercial Officer, shared his enthusiasm in welcoming the SAB members, who are esteemed leaders within their respective fields. Principe stated, "These founding members have proven their prowess in the industry, and their guidance will be invaluable as we embark on this important growth phase. We eagerly anticipate their influence in bolstering our organization through their contributions."

Meet the Founding Members

Among the established professionals on the Scientific Advisory Board are:

John Knight, Ph.D., founder of a UK-based consulting firm offering pivotal services in process chemistry and CMC, aimed at enhancing early-stage chemical development and facilitating project transitions. With nearly four decades in pharmaceuticals, Dr. Knight has a wealth of experience, previously holding positions at GSK and other notable firms.

Kamal Egodage, Ph.D., MBA, who leads Lasanth® Consulting, providing essential services from discovery to commercialization, focusing on CMC development and regulatory strategy. His extensive career includes significant contributions at top-tier companies such as Eli Lilly and Novartis, where he headed business development strategies for biologics.

Morris Rosenberg, D.Sc., with over 25 years of experience in therapeutic agent development, offers consulting services focusing on biologics and ADC therapies. His key contributions include pivotal roles in the development of numerous industry-changing therapies.

Scott Rudge, Ph.D., brings expertise from co-founding RMC Pharmaceutical Solutions and currently serves as a Principal Consultant at Syner-G. He has significant leadership experience in various biopharmaceutical sectors and is committed to advancing scientific and commercial strategies.

Steven Sandoval is the CEO and Operations Head at Pharmaceutical Technical Solutions, Inc. (PTSI), bringing over 30 years of biopharmaceutical experience to the table, specializing in manufacturing and CMC tech transfers.

Tatyana Touzova, the Chief Pharmaceutical Development & Manufacturing Officer at SERA Medicines, boasts over three decades of drug development expertise, overseeing critical operations from discovery to clinical stages.

About Abzena

Abzena stands as a premier bioconjugate and complex biologics CDMO + CRO, fully supporting the development of innovative treatments. The company is committed to collaborating with clients through integrated programs, focusing on mitigating risks and optimizing their development processes. With advanced facilities across several locations, Abzena excels in delivering tailored strategies that unlock the potential of therapeutic molecules, streamlining their progression to market. It is owned by Welsh, Carson, Anderson & Stowe, a recognized leader in private equity investment.

Frequently Asked Questions

What is the purpose of the Scientific Advisory Board at Abzena?

The Scientific Advisory Board is established to guide Abzena's innovation strategy and provide expert insights to enhance its growth.

Who are the key members of Abzena's Scientific Advisory Board?

The board includes industry leaders such as John Knight, Kamal Egodage, Morris Rosenberg, Scott Rudge, Steven Sandoval, and Tatyana Touzova.

How will the advisory board impact Abzena's operations?

By sharing their extensive industry knowledge, the advisory board members will help refine strategies that enhance the efficiency of moving medicines from concept to market.

What expertise do the board members bring to Abzena?

The members bring a wealth of experience in pharmaceuticals, regulatory strategy, product development, and commercialization, spanning several decades.

How does Abzena tailor its approach to clients?

Abzena customizes its strategies and services to meet the unique needs of each project, ensuring effective support throughout the development process.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.